



STATE MEDICAID DUR BOARD MEETING  
THURSDAY, March 13, 2014  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125



## MINUTES

**Board Members Present:**

Tony Dalpiaz, PharmD.  
Jay Aldus, DDS  
Mark Balk, PharmD.  
Michael Symond, M.D.

Jennifer Brinton, MD  
Susan Siegfried, M.D.  
Kyle Jones, M.D.

**Board Members Excused:**

George Hamblin, PharmD  
Keith Tolman, M.D.

Mr. Kumar Shah

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, PharmD.  
Trevor Smith C.Ph.T.  
Merelynn Berrett, R.N.

Lisa V Hunt, R.Ph.  
Heather Santacruz, R.N.  
Richard Sorenson, R.N.

**Other Individuals Present:**

Charissa Anne, J&J  
Kim Eggert, Gilead  
Mike Broadhead, Abbvie  
Joanita Lake, UofU  
Scott Larson, BMS

Laura Litzenburger, J&J  
Michele Pulyer, Gilead  
Tom McGovern, Abbvie  
Chad Burnham, Select Health  
Lisa Jenson, Gilead

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely announced that there will be two petitions following the meeting, and reminded everyone to sign-in.
3. **P&T Committee report** – Lisa Hunt addressed the board she reported that the P&T committee reviewed the short acting opioid agents. In March the committee will review appetite stimulants and antiemetic agents.
4. **Approval of prior meeting minutes** – Michael Symond made a motion to approve the February minutes. Kyle Jones seconds the motion. All in favor.
5. **Hepatitis C Drug Review** – Robyn Seely presented clinical evidence about Hepatitis C drugs including new agents, Olysio and Sovaldi.

## 6. Public Comment

- a. **Laura Litzenburger (Johnson & Johnson, Olysio)** – Reported drug information and clinical trials about Olysio.
- b. **Michelle Puyear (Gilead, Sovaldi)** – Reported drug information and clinical trials about Sovaldi.

## 7. Board Discussion

- a. Robyn Seely reported the high costs that all Hepatitis C drugs have, the cure rates, and the potential cost savings for patients who are cured from Hepatitis C.
- b. Mark Balk recommended that either all Hepatitis C agents have a PA placed on them or none.
- c. Robyn Seely showed that there has been little usage of the two Protease Inhibitors, Incivik and Victrelis in the past year, and the drugs were prescribed by specialists.
- d. Mark Balk said that because of the record of no misuse, he would recommend having no PA placed on any of the drugs.
- e. Jennifer Brinton said that doctors who specialize in treating Hepatitis C will prescribe with regards to the correct genotype and patient diagnosis. There could be problems with family practitioners who do not understand the diagnosis guidelines of this disease prescribing the incorrect course of treatment.
- f. Robyn Seely said that she believes that these drugs, while expensive, are worth it since it is a way to cure the disease. She said the many of the hepatitis C patients can cost much more than a regular patient in a year, and if the disease is eliminated from the patient, costs will be lower over future years.
- g. Mark Balk made a motion have no PA on Hepatitis C agents, Incivik, Victrelis, Olysio or Sovaldi. Michael Symond seconded the motion. All in favor.
- h. Because of petitions, the public DUR must be closed. Jennifer Brinton moved to close the public meeting, Mark Balk seconded the motion. All in favor.
- i. Meeting Adjourned.

The next DUR Board meeting is scheduled for Thursday, April 10, Daliresp (Roflumilast). Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)